Study for the effects of vildagliptin in combination with metformin on vascular endothelial function and systemic metabolism in patients with type 2 diabetes; multicenter, prospective, randomized, open-label, parallel group comparison

Trial Profile

Study for the effects of vildagliptin in combination with metformin on vascular endothelial function and systemic metabolism in patients with type 2 diabetes; multicenter, prospective, randomized, open-label, parallel group comparison

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Vildagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 15 Sep 2017 Primary endpoint (Flow-mediated dilation) has not been met as per the results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 18 Jan 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top